Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 126.04 USD 0.01%
Market Cap: 7.2B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Ascendis Pharma A/S
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ascendis Pharma A/S
Total Receivables Peer Comparison

Comparables:
GMAB
ZEAL
B
BAVA
F
FLUO
BIOPOR

Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Ascendis Pharma A/S
NASDAQ:ASND
Total Receivables
€80.7m
CAGR 3-Years
90%
CAGR 5-Years
99%
CAGR 10-Years
41%
Genmab A/S
CSE:GMAB
Total Receivables
kr6.2B
CAGR 3-Years
36%
CAGR 5-Years
48%
CAGR 10-Years
52%
Zealand Pharma A/S
CSE:ZEAL
Total Receivables
kr245.5m
CAGR 3-Years
28%
CAGR 5-Years
77%
CAGR 10-Years
25%
B
Bavarian Nordic A/S
CSE:BAVA
Total Receivables
kr1.1B
CAGR 3-Years
44%
CAGR 5-Years
59%
CAGR 10-Years
25%
F
Fluoguide AS
STO:FLUO
Total Receivables
kr6.4m
CAGR 3-Years
7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Total Receivables
kr13.4m
CAGR 3-Years
-6%
CAGR 5-Years
0%
CAGR 10-Years
3%

See Also

What is Ascendis Pharma A/S's Total Receivables?
Total Receivables
80.7m EUR

Based on the financial report for Jun 30, 2024, Ascendis Pharma A/S's Total Receivables amounts to 80.7m EUR.

What is Ascendis Pharma A/S's Total Receivables growth rate?
Total Receivables CAGR 10Y
41%

Over the last year, the Total Receivables growth was 126%. The average annual Total Receivables growth rates for Ascendis Pharma A/S have been 90% over the past three years , 99% over the past five years , and 41% over the past ten years .

Back to Top